QQQ   323.78 (+0.06%)
CGC   35.25 (+1.50%)
GE   13.21 (+0.76%)
MU   94.48 (-0.30%)
T   28.17 (+0.28%)
F   12.03 (+0.42%)
ACB   11.25 (+1.90%)
BA   224.93 (+0.24%)
BAC   35.69 (-0.28%)
QQQ   323.78 (+0.06%)
CGC   35.25 (+1.50%)
GE   13.21 (+0.76%)
MU   94.48 (-0.30%)
T   28.17 (+0.28%)
F   12.03 (+0.42%)
ACB   11.25 (+1.90%)
BA   224.93 (+0.24%)
BAC   35.69 (-0.28%)
QQQ   323.78 (+0.06%)
CGC   35.25 (+1.50%)
GE   13.21 (+0.76%)
MU   94.48 (-0.30%)
T   28.17 (+0.28%)
F   12.03 (+0.42%)
ACB   11.25 (+1.90%)
BA   224.93 (+0.24%)
BAC   35.69 (-0.28%)
QQQ   323.78 (+0.06%)
CGC   35.25 (+1.50%)
GE   13.21 (+0.76%)
MU   94.48 (-0.30%)
T   28.17 (+0.28%)
F   12.03 (+0.42%)
ACB   11.25 (+1.90%)
BA   224.93 (+0.24%)
BAC   35.69 (-0.28%)
Log in
NASDAQ:ARWR

Arrowhead Pharmaceuticals Competitors

$83.78
+4.12 (+5.17 %)
(As of 03/1/2021 12:00 AM ET)
Add
Compare
Today's Range
$81.06
Now: $83.78
$84.45
50-Day Range
$76.82
MA: $83.55
$90.47
52-Week Range
$19.51
Now: $83.78
$92.60
Volume567,615 shs
Average Volume817,059 shs
Market Capitalization$8.70 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.62

Competitors

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Vs. ALXN, BGNE, GMAB, HZNP, CTLT, and RPRX

Should you be buying ARWR stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Arrowhead Pharmaceuticals, including Alexion Pharmaceuticals (ALXN), BeiGene (BGNE), Genmab A/S (GMAB), Horizon Therapeutics Public (HZNP), Catalent (CTLT), and Royalty Pharma (RPRX).

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, earnings, dividends and risk.

Profitability

This table compares Arrowhead Pharmaceuticals and Alexion Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Arrowhead Pharmaceuticals-96.09%-17.37%-15.19%
Alexion Pharmaceuticals16.32%23.16%14.76%

Earnings & Valuation

This table compares Arrowhead Pharmaceuticals and Alexion Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arrowhead Pharmaceuticals$87.99 million98.83$-84,550,000.00($0.84)-99.74
Alexion Pharmaceuticals$4.99 billion6.69$2.40 billion$9.7415.60

Alexion Pharmaceuticals has higher revenue and earnings than Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

65.5% of Arrowhead Pharmaceuticals shares are held by institutional investors. Comparatively, 87.3% of Alexion Pharmaceuticals shares are held by institutional investors. 4.0% of Arrowhead Pharmaceuticals shares are held by company insiders. Comparatively, 4.0% of Alexion Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Arrowhead Pharmaceuticals and Alexion Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Arrowhead Pharmaceuticals031002.77
Alexion Pharmaceuticals017712.36

Arrowhead Pharmaceuticals currently has a consensus target price of $82.4286, indicating a potential downside of 1.61%. Alexion Pharmaceuticals has a consensus target price of $153.1250, indicating a potential upside of 0.76%. Given Alexion Pharmaceuticals' higher possible upside, analysts plainly believe Alexion Pharmaceuticals is more favorable than Arrowhead Pharmaceuticals.

Volatility and Risk

Arrowhead Pharmaceuticals has a beta of 1.62, meaning that its stock price is 62% more volatile than the S&P 500. Comparatively, Alexion Pharmaceuticals has a beta of 1.33, meaning that its stock price is 33% more volatile than the S&P 500.

Summary

Alexion Pharmaceuticals beats Arrowhead Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

BeiGene (NASDAQ:BGNE) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, dividends, earnings and analyst recommendations.

Earnings and Valuation

This table compares BeiGene and Arrowhead Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BeiGene$428.21 million68.23$-948,630,000.00($15.80)-20.21
Arrowhead Pharmaceuticals$87.99 million98.83$-84,550,000.00($0.84)-99.74

Arrowhead Pharmaceuticals has lower revenue, but higher earnings than BeiGene. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than BeiGene, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

60.7% of BeiGene shares are held by institutional investors. Comparatively, 65.5% of Arrowhead Pharmaceuticals shares are held by institutional investors. 9.0% of BeiGene shares are held by company insiders. Comparatively, 4.0% of Arrowhead Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Volatility and Risk

BeiGene has a beta of 0.91, meaning that its stock price is 9% less volatile than the S&P 500. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.62, meaning that its stock price is 62% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings for BeiGene and Arrowhead Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BeiGene22402.25
Arrowhead Pharmaceuticals031002.77

BeiGene currently has a consensus target price of $310.00, indicating a potential downside of 2.94%. Arrowhead Pharmaceuticals has a consensus target price of $82.4286, indicating a potential downside of 1.61%. Given Arrowhead Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Arrowhead Pharmaceuticals is more favorable than BeiGene.

Profitability

This table compares BeiGene and Arrowhead Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BeiGene-569.22%-56.81%-39.93%
Arrowhead Pharmaceuticals-96.09%-17.37%-15.19%

Summary

Arrowhead Pharmaceuticals beats BeiGene on 11 of the 14 factors compared between the two stocks.

Genmab A/S (NASDAQ:GMAB) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, earnings, profitability and institutional ownership.

Volatility and Risk

Genmab A/S has a beta of 0.93, indicating that its share price is 7% less volatile than the S&P 500. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.62, indicating that its share price is 62% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations for Genmab A/S and Arrowhead Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Genmab A/S34702.29
Arrowhead Pharmaceuticals031002.77

Genmab A/S presently has a consensus target price of $42.1429, suggesting a potential upside of 20.00%. Arrowhead Pharmaceuticals has a consensus target price of $82.4286, suggesting a potential downside of 1.61%. Given Genmab A/S's higher possible upside, research analysts clearly believe Genmab A/S is more favorable than Arrowhead Pharmaceuticals.

Profitability

This table compares Genmab A/S and Arrowhead Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Genmab A/S50.99%34.40%30.67%
Arrowhead Pharmaceuticals-96.09%-17.37%-15.19%

Valuation and Earnings

This table compares Genmab A/S and Arrowhead Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genmab A/S$804.57 million28.61$324.68 million$0.5168.86
Arrowhead Pharmaceuticals$87.99 million98.83$-84,550,000.00($0.84)-99.74

Genmab A/S has higher revenue and earnings than Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

6.2% of Genmab A/S shares are owned by institutional investors. Comparatively, 65.5% of Arrowhead Pharmaceuticals shares are owned by institutional investors. 4.0% of Arrowhead Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Genmab A/S beats Arrowhead Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Horizon Therapeutics Public (NASDAQ:HZNP) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, risk, valuation, dividends and profitability.

Profitability

This table compares Arrowhead Pharmaceuticals and Horizon Therapeutics Public's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Arrowhead Pharmaceuticals-96.09%-17.37%-15.19%
Horizon Therapeutics Public43.55%25.66%14.19%

Analyst Recommendations

This is a summary of current ratings and recommmendations for Arrowhead Pharmaceuticals and Horizon Therapeutics Public, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Arrowhead Pharmaceuticals031002.77
Horizon Therapeutics Public00803.00

Arrowhead Pharmaceuticals presently has a consensus target price of $82.4286, suggesting a potential downside of 1.61%. Horizon Therapeutics Public has a consensus target price of $101.8889, suggesting a potential upside of 10.86%. Given Horizon Therapeutics Public's stronger consensus rating and higher probable upside, analysts plainly believe Horizon Therapeutics Public is more favorable than Arrowhead Pharmaceuticals.

Insider and Institutional Ownership

65.5% of Arrowhead Pharmaceuticals shares are held by institutional investors. Comparatively, 88.6% of Horizon Therapeutics Public shares are held by institutional investors. 4.0% of Arrowhead Pharmaceuticals shares are held by insiders. Comparatively, 4.3% of Horizon Therapeutics Public shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Arrowhead Pharmaceuticals and Horizon Therapeutics Public's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arrowhead Pharmaceuticals$87.99 million98.83$-84,550,000.00($0.84)-99.74
Horizon Therapeutics Public$1.30 billion15.84$573.02 million$1.9447.38

Horizon Therapeutics Public has higher revenue and earnings than Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Horizon Therapeutics Public, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Arrowhead Pharmaceuticals has a beta of 1.62, meaning that its share price is 62% more volatile than the S&P 500. Comparatively, Horizon Therapeutics Public has a beta of 1.15, meaning that its share price is 15% more volatile than the S&P 500.

Summary

Horizon Therapeutics Public beats Arrowhead Pharmaceuticals on 11 of the 14 factors compared between the two stocks.

Catalent (NYSE:CTLT) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk and analyst recommendations.

Institutional & Insider Ownership

97.8% of Catalent shares are owned by institutional investors. Comparatively, 65.5% of Arrowhead Pharmaceuticals shares are owned by institutional investors. 1.0% of Catalent shares are owned by insiders. Comparatively, 4.0% of Arrowhead Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Volatility & Risk

Catalent has a beta of 1.5, meaning that its share price is 50% more volatile than the S&P 500. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.62, meaning that its share price is 62% more volatile than the S&P 500.

Profitability

This table compares Catalent and Arrowhead Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Catalent9.25%14.20%4.83%
Arrowhead Pharmaceuticals-96.09%-17.37%-15.19%

Earnings and Valuation

This table compares Catalent and Arrowhead Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Catalent$3.09 billion6.40$173 million$1.8861.91
Arrowhead Pharmaceuticals$87.99 million98.83$-84,550,000.00($0.84)-99.74

Catalent has higher revenue and earnings than Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Catalent, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Catalent and Arrowhead Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Catalent01702.88
Arrowhead Pharmaceuticals031002.77

Catalent presently has a consensus price target of $121.3750, indicating a potential upside of 4.27%. Arrowhead Pharmaceuticals has a consensus price target of $82.4286, indicating a potential downside of 1.61%. Given Catalent's stronger consensus rating and higher probable upside, analysts plainly believe Catalent is more favorable than Arrowhead Pharmaceuticals.

Summary

Catalent beats Arrowhead Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

Royalty Pharma (NASDAQ:RPRX) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both finance companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, earnings, profitability, institutional ownership and dividends.

Profitability

This table compares Royalty Pharma and Arrowhead Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Royalty PharmaN/AN/AN/A
Arrowhead Pharmaceuticals-96.09%-17.37%-15.19%

Insider and Institutional Ownership

40.9% of Royalty Pharma shares are held by institutional investors. Comparatively, 65.5% of Arrowhead Pharmaceuticals shares are held by institutional investors. 2.5% of Royalty Pharma shares are held by insiders. Comparatively, 4.0% of Arrowhead Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Royalty Pharma and Arrowhead Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Royalty PharmaN/AN/AN/AN/AN/A
Arrowhead Pharmaceuticals$87.99 million98.83$-84,550,000.00($0.84)-99.74

Royalty Pharma has higher earnings, but lower revenue than Arrowhead Pharmaceuticals.

Analyst Recommendations

This is a summary of recent ratings and price targets for Royalty Pharma and Arrowhead Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Royalty Pharma05402.44
Arrowhead Pharmaceuticals031002.77

Royalty Pharma presently has a consensus price target of $51.8750, indicating a potential upside of 8.01%. Arrowhead Pharmaceuticals has a consensus price target of $82.4286, indicating a potential downside of 1.61%. Given Royalty Pharma's higher possible upside, equities research analysts clearly believe Royalty Pharma is more favorable than Arrowhead Pharmaceuticals.

Summary

Arrowhead Pharmaceuticals beats Royalty Pharma on 5 of the 9 factors compared between the two stocks.


Arrowhead Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
1.9$151.97+0.5%$33.41 billion$4.99 billion35.51Increase in Short Interest
News Coverage
BeiGene logo
BGNE
BeiGene
1.1$319.39+0.2%$29.22 billion$428.21 million-15.80Earnings Announcement
Analyst Downgrade
Analyst Revision
Genmab A/S logo
GMAB
Genmab A/S
1.5$35.12+3.6%$23.02 billion$804.57 million27.23Increase in Short Interest
Analyst Revision
Gap Down
Horizon Therapeutics Public logo
HZNP
Horizon Therapeutics Public
2.4$91.91+1.1%$20.59 billion$1.30 billion25.11Earnings Announcement
Catalent logo
CTLT
Catalent
1.5$116.40+2.3%$19.81 billion$3.09 billion74.14
Royalty Pharma logo
RPRX
Royalty Pharma
1.4$48.03+3.0%$18.64 billionN/A0.00Gap Down
CureVac logo
CVAC
CureVac
0.6$96.18+2.0%$17.98 billionN/A0.00Decrease in Short Interest
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.6$148.75+0.4%$17.40 billion$219.75 million-19.00Analyst Report
Elanco Animal Health logo
ELAN
Elanco Animal Health
1.4$33.65+2.3%$15.88 billion$3.07 billion-59.04Earnings Announcement
Analyst Revision
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
1.9$79.17+2.2%$14.37 billion$1.70 billion18.12Earnings Announcement
Analyst Report
Teva Pharmaceutical Industries logo
TEVA
Teva Pharmaceutical Industries
1.4$10.92+1.5%$11.93 billion$16.89 billion-2.97Gap Down
Grifols logo
GRFS
Grifols
1.2$16.48+1.3%$11.33 billion$5.71 billion14.71
Bausch Health Companies logo
BHC
Bausch Health Companies
1.7$31.75+1.0%$11.28 billion$8.60 billion-5.83Earnings Announcement
Analyst Revision
BridgeBio Pharma logo
BBIO
BridgeBio Pharma
1.6$71.91+1.7%$10.70 billion$40.56 million-21.09Earnings Announcement
Analyst Revision
News Coverage
Gap Down
Mirati Therapeutics logo
MRTX
Mirati Therapeutics
1.4$203.72+1.4%$10.24 billion$3.34 million-26.46Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Dr. Reddy's Laboratories logo
RDY
Dr. Reddy's Laboratories
1.5$60.43+0.8%$10.01 billion$2.32 billion49.94
Ultragenyx Pharmaceutical logo
RARE
Ultragenyx Pharmaceutical
1.2$142.47+0.7%$9.54 billion$103.71 million-32.45Analyst Report
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
1.9$168.80+0.5%$9.51 billion$2.16 billion53.25Earnings Announcement
Analyst Report
Increase in Short Interest
Analyst Revision
Zai Lab logo
ZLAB
Zai Lab
1.2$162.02+8.9%$9.41 billion$12.98 million-53.47News Coverage
Ascendis Pharma A/S logo
ASND
Ascendis Pharma A/S
1.3$156.30+0.9%$8.35 billion$14.98 million-19.04
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.6$49.56+1.2%$7.88 billion$339.08 million-28.81Earnings Announcement
Analyst Revision
News Coverage
Schrödinger logo
SDGR
Schrödinger
1.3$113.09+9.4%$7.86 billion$85.54 million0.00Upcoming Earnings
Gap Down
United Therapeutics logo
UTHR
United Therapeutics
1.7$171.27+2.4%$7.63 billion$1.45 billion16.20Earnings Announcement
Analyst Report
Analyst Revision
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.4$54.05+3.1%$7.61 billion$1.12 billion112.60Earnings Announcement
Analyst Upgrade
Analyst Revision
News Coverage
Gap Down
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$87.03+0.0%$6.87 billion$380.83 million-11.13Earnings Announcement
News Coverage
GW Pharmaceuticals logo
GWPH
GW Pharmaceuticals
1.5$214.91+0.3%$6.67 billion$311.33 million-124.95Decrease in Short Interest
Allakos logo
ALLK
Allakos
1.7$118.29+2.4%$6.21 billionN/A-43.17Earnings Announcement
News Coverage
Maravai LifeSciences logo
MRVI
Maravai LifeSciences
1.9$36.47+10.8%$6.15 billionN/A0.00Analyst Report
News Coverage
Gap Down
AVIR
Atea Pharmaceuticals
1.7$73.77+2.2%$6.09 billionN/A0.00Decrease in Short Interest
TG Therapeutics logo
TGTX
TG Therapeutics
1.8$45.00+2.7%$5.92 billion$150,000.00-21.23
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.9$121.22+2.7%$5.84 billionN/A-34.54Earnings Announcement
Analyst Downgrade
News Coverage
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$100.13+1.9%$5.80 billion$66.51 million18.47
Perrigo logo
PRGO
Perrigo
2.6$42.26+4.5%$5.77 billion$4.84 billion-704.22Earnings Announcement
Dividend Increase
High Trading Volume
News Coverage
Gap Down
Galapagos logo
GLPG
Galapagos
1.3$84.63+2.4%$5.54 billion$1.00 billion-12.82
Emergent BioSolutions logo
EBS
Emergent BioSolutions
1.8$102.20+6.1%$5.45 billion$1.11 billion32.86Gap Down
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
1.4$86.38+1.6%$5.18 billionN/A-7.04Earnings Announcement
Analyst Report
News Coverage
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.2$87.28+2.6%$5.10 billion$6.87 million-8.43Earnings Announcement
Analyst Revision
News Coverage
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.3$80.08+0.3%$4.83 billion$806.43 million-11.34
Eidos Therapeutics logo
EIDX
Eidos Therapeutics
1.0$122.21+0.0%$4.75 billion$26.69 million-46.12News Coverage
ChemoCentryx logo
CCXI
ChemoCentryx
1.4$68.40+0.8%$4.73 billion$36.13 million-102.09Earnings Announcement
Analyst Report
Insider Selling
Decrease in Short Interest
News Coverage
IMAB
I-Mab
0.9$63.97+7.5%$4.60 billion$4.31 million-2.21
FibroGen logo
FGEN
FibroGen
1.4$50.53+1.0%$4.60 billion$256.58 million-19.36Earnings Announcement
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$30.06+4.4%$4.38 billion$204.89 million-37.58Upcoming Earnings
Gap Down
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$126.63+3.5%$4.32 billion$26.52 million-11.16Earnings Announcement
News Coverage
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.1$23.62+3.9%$4.24 billion$114.62 million-9.52Earnings Announcement
Analyst Report
Analyst Revision
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.1$58.16+1.8%$3.97 billion$306.98 million-8.32Earnings Announcement
Analyst Revision
Insmed logo
INSM
Insmed
1.2$37.73+5.2%$3.84 billion$136.47 million-14.51Earnings Announcement
Gap Down
Arvinas logo
ARVN
Arvinas
2.0$77.30+1.3%$3.74 billion$42.98 million-30.20Earnings Announcement
Analyst Downgrade
News Coverage
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$47.68+1.0%$3.61 billionN/A-6.43Earnings Announcement
LEGN
Legend Biotech
1.2$26.43+2.8%$3.49 billion$64.39 million0.00Increase in Short Interest
Gap Down
This page was last updated on 3/2/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.